Breakthroughs and Challenges of a New Era in ADPKD Care
Over the last three years, the management of patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD) has fundamentally transformed through various advances. Diagnosis is often aided by low-cost next-generation sequencing platforms, and robust risk-stratification strategies identify high-risk patients who may benefit from recently approved treatments. Differences are emerging between ADPKD-specific supportive care and general CKD management. Translating these breakthroughs to clinical practice can be complicated.
This program efficiently addresses these breakthroughs and their accompanying challenges: the diagnostic and risk assessment tools, Food and Drug Administration (FDA) approvals, health disparities, and patient concerns.